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Abstract CCN2, a classical member of the CCN family of
matricellular proteins, is a key molecule that conducts
cartilage development in a harmonized manner through
novel molecular actions. During vertebrate development, all
cartilage is primarily formed by a process of mesenchymal
condensation, while CCN2 is induced to promote this
process. Afterwards, cartilage develops into several sub-
types with different fates and missions, in which CCN2
plays its proper roles according to the corresponding
microenvironments. The history of CCN2 in cartilage and
bone began with its re-discovery in the growth cartilage in
long bones, which determines the skeletal size through the
process of endochondral ossification. CCN2 promotes
physiological developmental processes not only in the
growth cartilage but also in the other types of cartilages, i.
e., Meckel’s cartilage representing temporary cartilage
without autocalcification, articular cartilage representing
hyaline cartilage with physical stiffness, and auricular
cartilage representing elastic cartilage. Together with its
significant role in intramembranous ossification, CCN2 is
regarded as a conductor of skeletogenesis. During cartilage
development, the CCN2 gene is dynamically regulated to
yield stage-specific production of CCN2 proteins at both
transcriptional and post-transcriptional levels. New func-
tional aspects of known biomolecules have been uncovered
during the course of investigating these regulatory systems
in chondrocytes. Since CCN2 promotes integrated regener-
ation as well as generation (=development) of these tissues,
its utility in regenerative therapy targeting chondrocytes
and osteoblasts is indicated, as has already been supported
by experimental evidence obtained in vivo.
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Re-discovery of CCN2 in growth cartilage
CCN2, also known as connective tissue growth factor
(CTGF), was originally identified in 1991 as a platelet-
derived growth factor-related protein with mitogenic activ-
ity toward fibroblasts (Bradham et al. 1991), which finding
prompted the initial name given to this molecule. After-
wards, at least 8 different names were given to this single
molecule (Perbal and Takigawa 2005), until the unified
nomenclature was finally proposed in 2003 (Brigstock et al.
2003). As a result, CCN2 was given as the name for this
second-oldest known molecule among the 6 CCN family
members, based on this new terminology.
During this emerging period, a gene segment that was
specifically expressed in hypertrophic chondrocytes in the
mouse growth plate was cloned from the cDNA obtained
from human chondrocytic HCS-2/8 cells (Takigawa et al.
1989) via the differential display PCR method (Nakanishi
et al. 1997). This molecular clone was designated hyper-
trophic chondrocyte-specific gene 24 (Hcs-24). Nucleotide
sequence analysis of this clone revealed that Hcs-24 was
identical to Ctgf. Starting from this re-discovery of CTGF
in growth plate cartilage and a human chondrocytic cell
line, critical roles of CCN2 in chondrocytes have been
uncovered up to today.
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Cartilage is a connective tissue characterized physically by its
proper elasticity. This tissue is avascular, and the cells are
surrounded by a vast amount of extracellular matrix (ECM).
Therefore,signaltransmissionto/fromchondrocytesgenerally
occurs via the interaction of signaling factors with cartilagi-
nous ECM molecules, which is referred to as a matricrine
molecular action (Chen and Lau 2009). In such a microen-
vironment, an extracellular information network is formed on
the basis of the ECM scaffold. For the harmonized formation
and maintenance of this network, CCN2 is thought to be
required, because of its novel structure and functionality
(Kubota and Takigawa 2007).
CCN2 is recognized as a multifunctional key player in the
development of mesenchymal tissues and is also known to be
involved in pathological conditions represented by various
fibrotic diseases and malignancies (Perbal and Takigawa
2005; Leask et al. 2009; Chen and Lau 2009;C h e ne ta l .
2011). Similar to the other CCN family members, CCN2 is
composed of 4 distinct modules connected in tandem, which
are insulin-like growth factor binding protein-like (IGFBP),
von Willebrand factor type C repeat (VWC), thrombospon-
din type 1 repeat (TSP1), and C-terminal cystine knot (CT)
modules (Perbal 2004;L e a s ka n dA b r a h a m2006,K u b o t a
and Takigawa 2007; Chen and Lau 2009). Since all of these
modules are highly interactive with a number of other
molecules, CCN2, as a 4-handed matricellular conductor, is
able to manipulate the behavior of these counterparts to
integrate their actions (Fig. 1). Indeed, binding of CCN2 to
ECM molecules such as aggrecan, heparan sulfate proteo-
glycans, and fibronectin (Aoyama et al. 2009; Gao and
Brigstock 2004; Nishida et al. 2003; Hoshijima et al. 2006);
to cell-surface receptors such as integrins, low-density
lipoprotein receptor-related protein 1 (LRP1) and Trk A
(Jedsadayanmata et al. 1999; Segarini et al. 2001; Kawata et
al. 2006;A s a u m ie ta l .2000; Wahab et al. 2005); to growth
factors such as transforming growth factor β (TGF- β), bone
morphogenetic proteins (BMPs), and vascular endothelial
growth factor (VEGF) (Abreu et al. 2002; Maeda et al. 2009;
Inoki et al. 2002); and even to certain CCN family members
h a sb e e np r o v e ne x p e r i m e n t a l l y( H o s h i j i m ae ta l .2011). It
should be noted here that all of the molecules mentioned
above are present in cartilage. As detailed in the following
sections of this review, CCN2 plays critical roles in cartilage
development, maintenance, and regeneration via complex
interactions with these molecules.
Classification of cartilage in vertebrates
During the course of evolution, cartilage appeared to
furnish the body with an endoskeleton. In early vertebrates,
as represented by lampreys, the endoskeleton is totally
composed of cartilaginous tissues; whereas major portions
of skeletal parts are eventually replaced with calcified bone
tissue in later vertebrates (Kubota and Takigawa 2007).
However, as development repeats evolution, most of our
skeletal parts are initially formed as cartilage anlagen,
followed by the growth of the cartilage and gradual
replacement with bone (Karaplis 2002). However, quite
limited parts are left uncalcified to form tissues/organs with
the physical property of elasticity. From this point of view,
cartilage can be roughly classified into 2 distinct classes:
temporary and permanent cartilages (Fig. 2). Among the
temporary cartilages, most of them undergo growth and
direct replacement with bone, which process is typically
observed in the endochondral ossification of long bones
(Karaplis 2002); whereas the others simply disappear
during the development of the corresponding bones (Couly
et al. 1993). Meckel’s cartilage and the notochord represent
the latter class of temporary cartilages. In the case of
permanent cartilage, the relevant tissues can be classified
into 3 groups based on their physical property and ECM
composition (Fig. 2). The first group is that with physical
stiffness, which is represented by the articular cartilage
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Fig. 1 Molecular action of CCN2 in cartilage. CCN2 molecule
represented by the complex with 4 spheres in the center interacts with
a number of biomolecules in different categories, which results in the
integrated manipulation of extracellular signaling. The letters “I,”“ V,”
“T,” and “C” on the spheres denote insulin-like growth factor-like
module, von Willebrand factor type C repeat, thrombospondin type 1
repeat and C-terminal cystine knot module, respectively. Growth
factors interacting with CCN2 include transforming growth factor beta
(TGF-β), bone morphogenetic proteins (BMPs) and vascular endo-
thelial growth factor (VEGF). Binding between CCN2 and cartilag-
inous ECM molecules, such as fibronectin (Fn) and aggrecan, is
indicated. Several cell-surface receptors present on chondrocytes as
represented by integrins (Itg), low-density lipoprotein receptor related
protein 1 (LRP-1) and Trk A are known to directly interact with
CCN2. Of note, recent investigation is revealing the interaction of
CCN2 with another CCN family member, as well as with itself
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high level of elasticity, typically observed in ears; and the
third group is rich in collagen fibers, adding flexibility to
this tissue. Surprisingly, CCN2 has been shown to promote
the development of most of these different types of
cartilages, as described below.
CCN2 in the growth plate
In vertebrates, all of the long bones and major skeletal
components develop through a process known as endochon-
dral ossification, whereas craniofacial bones and other minor
skeletal parts are constructed via intramembranous ossifica-
tion or via an intermediate/mixed process of the two (Karaplis
2002). During this process, the growth plate chondrocytes
inside the bone or cartilage anlagen play a major role,
particularly in bone growth. Therefore, endochondral ossifi-
cation can be regarded as a critical biological process that
determines the body height, in which CCN2 plays a central
role to conduct all of the events of this process (Fig. 3).
After the formation of cartilage anlagen, growth plates
are formed near both ends, facing the ossification centers.
Here, chondrocytes undergo a series of differentiation steps
to grow and calcify the bones. Along with bone growth,
resting chondrocytes in a deep zone of the cartilage begin to
proliferate and undergo maturation, producing a cartilagi-
nous ECM including type II collagen and aggrecan as
components, in order to support the bone growth. At the
final step, chondrocytes differentiate into the hypertrophic
chondrocytes that trigger matrix vesicle-mediated calcifica-
tion, while producing type X collagen and matrix metal-
loproteinase (MMP)-13, and are then removed by
phagocytosis by chondroclasts and/or apoptosis. Thereafter,
osteoblasts and vascular endothelial cells are recruited to
replace the hypertrophic layer of growth cartilage with bone
tissue. As mentioned in a previous section, CCN2 was
initially found specifically in the hypertrophic layer of the
growth plate; and later, pre-hypertrophic chondrocytes were
confirmed to be the major producer of CCN2. Since CCN2
is a matricellular protein, it can be stored in, and infiltrate
through, the ECM. In fact, immunohistochemical staining
of CCN2 shows strong signals in pre-hypertrophic and
hypertrophic layers and significant signals in proliferating
layer and cartilage-bone junction in the growth plate. Of
importance, it has also been shown that CCN2 promotes the
proliferation and differentiation of osteoblasts, osteoclasts,
and vascular endothelial cells (Nishida et al. 2000; Safadi et
al. 2003; Shimo et al. 1999; Nishida et al. 2011), as well as
the chondrocytes themselves in vitro (Nakanishi et al.
2000). Additionally, the growth plate-produced CCN2 may
be a possible source of the CCN2 accumulated in platelets
(Cicha et al. 2004; Kubota et al. 2004; Sumiyoshi et al.
2010). Collectively, the mission of CCN2 in the growth
plate is to promote all of the steps of bone formation in a
harmonized manner (Kubota and Takigawa 2007). These
indications are firmly supported by the phenotype of ccn2-
null mice. In such mice, the growth plate is characterized
by an abnormal morphological appearance with an enlarged
hypertrophic layer (Ivkovic et al. 2003). From functional
aspects, endochondral ossification is on the whole delayed;
and ECM production is depressed therein, which features
are accompanied, interestingly, by an unusual induction of
CCN3 with counteracting functions (Kawaki et al. 2008a).
Such a role of CCN2 in endochondral ossification is also
represented by the fact that CCN2 accelerates bone
regeneration (Kikuchi et al. 2008), in which endochondral
ossification recurs (Nakata et al. 2002).
These pleiotropic effects of CCN2 on chondrocytes are
known to be mediated by multiple intracellular second
messengers of signal transduction, which include protein
kinase C (PKC); mitogen-activated protein kinases (MAPKs)
such as p38MAPK, extracellular regulated protein kinase
(ERK), and c-Jun N-terminal kinase (JNK); phosphoinositide
3-kinase (PI3K); and protein kinase B (PKB) (Yosimichiet al.
2006). CCN2 supposedly ignites these signaling pathways
either directly via cell-surface receptors or indirectly via
other extracellular cofactors, resulting in the initiation of
these multiple signaling cascades.
CCN2 in Meckel’s cartilage
Meckel’s cartilage arises from mesodermal progenitor cells
situated in close proximity to the zone of mineralization
Cartilage
Permanent
Temporary
Growth plate
Meckel’s
Typical
Bone-directed
Bone-inducing
Auricular Elastic
Meniscus Fibrous
Articular Hyaline
Fig. 2 Classification of cartilage present in vertebrates. Temporary
cartilage appears during development to accomplish skeletal formation
and growth. A class of temporary cartilage, here termed bone-directed
cartilage, itself is mineralized to become bone under the collaboration
with osteoblasts and vascular endothelial cells. In the case of bone-
inducing cartilage, bone is formed independently at a space in close
proximity. Permanent cartilage is formed and maintained to add
elasticity and stiffness required in certain organs. Based on the
physical property, histological characteristics, and ECM composition,
permanent cartilage can be classified as hyaline, elastic or fibrous
The role of CCN2 in cartilage and bone development 211during mandibular bone formation (Couly et al. 1993). The
chondrocytes involved therein also go through a differen-
tiation process similar to that of growth plate chondrocytes;
however, Meckel’s cartilage never calcifies itself. Interest-
ingly, in spite of the jaw-like shape of the Meckel’s
cartilage, the mineralized jaw is constructed by an intra-
membranous ossification process occurring at a zone facing
the cartilage (Mina 2001); and, thereafter, Meckel’s
cartilage disappears. The fate of this transient cartilage is
reminiscent of that of the notochord, which leaves the
nucleus pulposus as its memento. Of note, nucleus pulposus
cells also produce CCN2 (Erwin et al. 2006)
The role of CCN2 in Mechel’s cartilage was investigated
and reported in 2004 by Shimo et al. Enhanced ccn2
expression is observed in 2 distinct developmental stages,
one being mesenchymal condensation and the other,
hypertrophic-like late differentiation. Also, application of
recombinant CCN2 (rCCN2) to cultured chondrocytes
isolated from Meckel’s cartilage stimulates the condensa-
tion and later differentiation of those cells (Shimo et al.
2004). It should be noted that CCN2 acts through the ECM
on the proximal cell population and promotes the differen-
tiation and proliferation of osteoblasts. Although Meckel’s
cartilage itself does not metamorphose into mandibular
bone, the hypertrophic chondrocytes therein produce CCN2
that recruits osteoblasts and promotes bone formation.
Therefore, basically, the roles of chondrocytes and CCN2
in intramembranous jaw bone formation may not remark-
ably differ from those in the growth plate.
CCN2 in articular cartilage
Articular cartilage is the permanent cartilage that enables
the flexible movement between bones connected by a joint.
Like growth-plate cartilage, this tissue originates from the
same cartilage anlagen, but remains unmineralized at the
end of the bone even after the completion of skeletal
growth (Karaplis 2002). Thus, chondrocytes in this type of
cartilage do not undergo hypertrophic differentiation to-
wards calcification, except under pathological conditions.
The most common pathological change found clinically in
articular cartilage is osteoarthritis (OA). After a long time
of mechanical overload or another equivalent stimulus,
articular cartilage is damaged physically and by inflamma-
tion, which damage is accompanied by cluster formation
and abnormal hypertrophic changes in chondrocytes,
eventually forming osteophytes.
In early studies, CCN2 was found to promote the
proliferation and maturation of articular chondrocytes
(Nishida et al. 2002); however, in contrast to the growth-
plate chondrocytes, this factor does not promote the
hypertrophic differentiation of articular chondrocytes. In
OA cartilage, overexpression of CCN2 is frequently ob-
served among the OA articular chondrocytes forming
clusters (Omoto et al. 2004). Considering these findings
taken together, it is hypothesized that CCN2 is produced by
articular chondrocytes in response to OA injury, in order to
regenerate the damaged cartilage by promoting the prolifer-
ation of and ECM synthesis by articular chondrocytes
Promotion of cartilage growth Promotion of ossification
Hypertrophic
Osteoblasts
VE cells
Osteo/chondroclasts
C
C
C
C
C
C
Resting Proliferative Pre-hypertrophic
Fig. 3 Endochondral ossification by growth plate cartilage and role of
CCN2. Inside of long bones, chondrocytes in the growth plate
undergo a series of differentiation processes to execute the bone
growth. CCN2 is mainly produced by growth plate chondrocytes in
the prehypertrophic and hypertrophic layers and infiltrates through the
ECM in both directions. Chondrocytes located most distantly from the
CCN2 producers are less stimulated by CCN2 and stay at rest. Those
located nearby the prehypertrophic ones are strongly stimulated in a
matricrine manner to proliferate and maturate to produce cartilaginous
ECM, which confers longitudinal bone growth. Prehypertrophic
chondrocytes themselves are stimulated by CCN2 in an autocrine/
intracrine manner and forwarded to terminal differentiation toward
apoptosis. CCN2 released to the bone marrow acts on osteoblasts,
vascular endothelial (VE) cells, and osteoclasts to promote the
replacement of cartilaginous tissue with vascularized bone and bone
remodeling. C: CCN2 molecule
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in which full-thickness defect in articular cartilage was
repaired, and experimentally induced OA was ameliorated,
by externally applied rCCN2 (Nishida et al. 2004). Further-
more, a recent study indicated that forced expression of ccn2
in cartilaginous tissues in mice results in the acquisition of an
OA-resistant phenotype (Itoh et al. 2010).
CCN2 in auricular cartilage
In humans, pinnae may not have a critical function in
biological life, but they are still esthetically important parts
ofourfaces.Fromthispointofview,regulatedregenerationof
auricularcartilageisdesirableinthecaseoftraumaticinjuryto
the pinna. In contrast to articular cartilage, auricular cartilage
is characterized by a more elastic physical property, which is
provided by the inclusion of elastin fibers, suggesting a
differentmolecular background. In2008, effects ofrCCN2 on
auricular chondrocytes from normal rabbits were evaluated.
The results showed, however, quite similar effects to those on
articular chondrocytes. Namely, rCCN2 promoted both the
proliferation and differentiation of these cells, including the
abilitytoproduce elastin,a markerofelastic cartilage,without
inducing abnormal hypertrophy. Finally, ex vivo application
of rCCN2 was shown to also promote the generation of
auricular cartilage, further suggesting the integrated effect of
CCN2 on cartilage generation and repair (Fujisawa et al.
2008).
Intramembranous ossification and CCN2
Although most skeletal parts are developed and grow
through endochondral ossification, clavicle and cranial
bones are directly formed by osteoblasts without passing
through the cartilaginous stage, which is called intra-
membranous ossification. In this process, osteoblasts are
differentiated directly from the nodules of condensed
mesenchymal stem cells to deposit type I collagen and
calcifying ECM components (Karaplis 2002). During the
course of animal evolution, the exoskeleton was developed
earlier than the endoskeleton. The former is constructed
without cartilaginous anlagen, whereas the prototype of the
latter is cartilage. This fundamental difference between
these 2 types of bones is seen in Brachyura (Crab), which
has a strong calcified exoskeleton and minor cartilaginous
endoskeleton. Therefore, the cranial bones surrounding the
brain may be regarded as working fossils in our skeleton.
Interestingly, a prototypic gene of ccn2 c a nb ef o u n de v e n
in the genome of Drosophila melanogaster (fruit fly), which
has no endoskeleton, suggesting a basic role of CCN2 in
general skeletogenesis. Consistent with such an assumption
and the fact that CCN2 promotes the formation, proliferation,
and differentiation of osteoblasts in vitro (Nishida et al. 2000;
Safadi et al. 2003; Smerdel-Ramoya et al. 2008), CCN2 was
found to be required for proper intramembranous ossification
in vivo and in vitro through studies on conventional and
conditional ccn2-null mice (Kawaki et al. 2008b; Canalis et
al. 2010). Furthermore, the attenuated ossifying ability of
ccn2-null osteoblasts is rescued by exogenously added
rCCN2 (Kawaki et al. 2008b). Thus, CCN2 is now
considered to conduct the formation of all of the skeletal
parts, following the proper scenario given to each part.
Gene regulation during chondrocyte differentiation
As stated in other subsections, during the course of the
differentiation after mesenchymal condensation, strong
Proliferation 
& maturation Chondrogenesis
Articular cartilage regeneration OA
Mesenchymal 
stem cells Articular chondrocytes
promotion C C
ECM 
production
C
Fig. 4 CCN2 in articular cartilage under physiological and patholog-
ical situations. CCN2 is known to promote all of the physiological
steps towards articular cartilage formation without promoting patho-
logical hypertrophic changes in articular chondrocytes (right). In
osteoarthritis (OA) cartilage, CCN2 production is strongly induced in
articular chondrocytes in order to increase the cell number and
compensate the ECM deficiency, which results in the formation of the
chondrocyte clusters typically observed in OA cartilage. This
hypothetical action of CCN2 in articular cartilage is strongly
supported by the fact that CCN2 regenerates the tissue lost in a full-
thickness defect of articular cartilage in vivo. C: CCN2 molecule
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differentiation of chondrocytes. The mechanism that induces
the ccn2 gene has been investigated at both transcriptional
and post-transcriptional levels. Although a number of studies
have been performed to clarify the transcriptional regulatory
system of the CCN2 gene in various cells, relevant studies
with chondrocytic cells are limited (Leask and Abraham
2006; Kubota and Takigawa 2007). However, post-
transcriptional regulation of ccn2 has been investigated,
usually in the context of chondrocyte biology. The findings
currently available on this issue are summarized in Fig. 5.
It is widely recognized that CCN2 production is strongly
induced by TGF-β via a transcriptional mechanism (Leask
and Abraham 2006). Also in chondrocytes, this regulation
appears dominant; and it was reported that the induction of
ccn2 by TGF-β is partly dependent on the known cis-acting
sequence in the Ccn2 proximal promoter. This induction
could be the net effect of the direct action by TGF-β and an
indirect effect through endothelin 1. Of further interest,
another transcriptional enhancer dominant in chondrocytes
(TRENDIC) has been identified (Eguchi et al. 2002).
TRENDIC is also located in the proximal promoter region
and mediates ccn2 induction in a stronger manner in
chondrocytes than in other types of the cells. Subsequent
study identified matrix metalloproteinase 3 (MMP-3) as
being a TRENDIC-binding protein (Eguchi et al. 2008).
Surprisingly, this report thus unveiled this unexpected
functional property of MMP-3, which had been previously
regarded only as an ECM-degradating enzyme.
Hypoxic regulation of CCN2 production is known to
occur in chondrocytic cells, in which a post-transcriptional
regulatory element in the 3′-untranslated region, termed cis-
acting element of structure-anchored repression (CAE-
SAR), mediates the regulation of the mRNA stability by a
CAESAR-binding protein (Kubota et al. 2000; Kondo et al.
2006). Contribution of post-transcriptional regulatory
events to the stage-specific induction of CCN2 during
chondrocytic differentiation was investigated with chicken
embryonic chondrocytes. Then, nucleophosmin (NPM/
B23) was re-discovered as being a specific RNA-binding
regulator of the degradation of ccn2 mRNA. According to
this study, down-regulation of NPM, which had been
previously known only as a histone chaperon, eventually
stabilizes the ccn2 mRNA to increase the steady-state level
of the mRNA upon hypertrophic differentiation (Mukudai
et al. 2008). This regulation is mediated by a cis-element in
the 3′-UTR other than CAESAR and, interestingly, is
chondrocyte specific. Additionally, a recent report indicated
a repressive effect on the chondrocyte phenotype by a
micro RNA (Siomi and Siomi 2009), miR-18a, which is
mediated, at least in part, through translational repression of
the Ccn2 mRNA (Ohgawara et al. 2009). All of these post-
ccn2 mRNA
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AAAAA
3'-UTR
AAAAA
ccn2 gene
CAESAR3 ’ - 1 00/50 miR-18 target
Hypoxia
TRENDIC BCE-1 Ets-1
TATA
TGF-ß ET-1 TGF-ß
MMP-3
NPM miR-18
Fig. 5 Transcriptional and post-transcriptional regulation of the
CCN2 gene in chondrocytes. Transcriptional regulation observed in
chondrocytes or chondrocytic cells is summarized in the upper-half,
while post-transcriptional regulation is schematized in the lower half.
TGF-β is known to enhance the CCN2 expression in chondrocytes, as
well as in a number of other types of cells. This regulation is
supposedly mediated by 3 genetic cis-elements: Smad-binding
element (SBE), basal control element (BCE), and Ets1-binding
sequence in the proximal promoter, directly or indirectly through
endothelin-1 (ET-1). Hatched arrows indicate the actions experimen-
tally indicated from studies using non-chondrocytic cells. MMP-3 is
shown to directly bind to TRENDIC to enhance transcription. The
RNA stability and translation of the CCN2 mRNA is regulated by
direct interaction with nucleophosmin (NPM) and miR-18a through
their specific targets in the 3′-untranslated region (UTR). The cis-
acting element of structure-anchored repression (CAESAR) mediates
the post-transcriptional regulation by factor(s) yet to be identified.
TATA, ORF and AAAAA represent the TATA box, open reading
frame and polyadenyl tail, respectively
214 S. Kubota, M. Takigawatranscriptional regulations take place in the 3′-UTR, which
is consistent with the fundamental rule of gene regulation
that has been conserved throughout animal evolution
(Merritt et al. 2008). In addition, retinoic acid drastically
increases the steady-state level of ccn2 mRNA specifically
in hypertrophic chondrocytes through MAPK-mediated
signaling, although its precise mechanism remains to be
clarified (Shimo et al. 2005)
Medical utility of CCN2 and its derivatives
As introduced above, the molecular actions of CCN family
members are based on multiple interactions with numerous
molecules, which support the integrated and harmonized
promotion of tissue development. Therefore, CCN2 is
thought to be an ideal molecule to be utilized in the
regenerative therapy of various types of cartilages and bone.
The utility of CCN2 in the regeneration of damaged articular
cartilage and bone was already proven in vivo (Nishida et al.
2004; Kikuchi et al. 2008; Ono et al. 2008), which may
lead to the development of a novel anti-OA therapeutic.
Similarly, CCN2 may possibly be employed to construct a
bioengineered pinna ex vivo for plastic surgery. Moreover,
if we could control the CCN2 in the growth plate, we may
be able to control body height and shape during the
growing period, which may be called “skeletal designing.”
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